VTGN vs. ABEO, IMUX, RNAC, KPTI, COYA, NVCT, CLRB, AMLX, OPTN, and RZLT
Should you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Abeona Therapeutics (ABEO), Immunic (IMUX), Cartesian Therapeutics (RNAC), Karyopharm Therapeutics (KPTI), Coya Therapeutics (COYA), Nuvectis Pharma (NVCT), Cellectar Biosciences (CLRB), Amylyx Pharmaceuticals (AMLX), OptiNose (OPTN), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.
Vistagen Therapeutics (NASDAQ:VTGN) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.
Vistagen Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
Abeona Therapeutics received 232 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. However, 72.24% of users gave Vistagen Therapeutics an outperform vote while only 70.27% of users gave Abeona Therapeutics an outperform vote.
Abeona Therapeutics has higher revenue and earnings than Vistagen Therapeutics.
78.4% of Vistagen Therapeutics shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 1.0% of Vistagen Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Abeona Therapeutics has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -3,073.51%. Vistagen Therapeutics' return on equity of -72.10% beat Abeona Therapeutics' return on equity.
Vistagen Therapeutics currently has a consensus target price of $19.00, suggesting a potential upside of 319.43%. Abeona Therapeutics has a consensus target price of $36.00, suggesting a potential upside of 737.21%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Vistagen Therapeutics.
In the previous week, Abeona Therapeutics had 2 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 6 mentions for Abeona Therapeutics and 4 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 0.73 beat Abeona Therapeutics' score of 0.73 indicating that Vistagen Therapeutics is being referred to more favorably in the media.
Summary
Abeona Therapeutics beats Vistagen Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Vistagen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vistagen Therapeutics Competitors List
Related Companies and Tools
